Prasugrel, a third generation thienopyridine and potent platelet inhibitor.
Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.
Gurbel
Paul A
PA
Sinai Center for Thrombosis Research, Hoffberger Building, Suite 56, 2401 West Belvedere Avenue, Baltimore, MD 21215, USA. pgurbel@lifebridgehealth.org
Tantry
Udaya S
US
D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D010330:Patents as Topic; D010879:Piperazines / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000068799:Prasugrel Hydrochloride; D013329:Structure-Activity Relationship; D013876:Thiophenes / Q000009:adverse effects / Q000138:chemical synthesis / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D013923:Thromboembolism / Q000188:drug therapy*
D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D013876:Thiophenes; D000068799:Prasugrel Hydrochloride